GlassScriptPhysician profile
Melissa E Sanders
NPI 1184156804
$3,240.34
in general payments reported to CMS, 2019-2025
27 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.15 · 2020: $212 · 2021: $345 · 2022: $265 · 2023: $737 · 2024: $845 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,198.14 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $446.52 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $362.00 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $241.39 | 2020-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $141.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.31 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $87.05 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.91 | 2022 | |
| Glaxosmithkline, LLC. | $74.03 | 2020-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $59.65 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.38 | 2024-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $57.42 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $50.16 | 2022-2023 | Contrave |
| Biohaven Pharmaceuticals, INC. | $42.10 | 2020-2021 | |
| Eisai INC. | $32.77 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.56 | 2023 | |
| Abbott Laboratories | $24.66 | 2025 | Proclaim |
| Inari Medical, INC. | $19.18 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Takeda Pharmaceuticals U.S.A., INC. | $18.25 | 2022 | |
| Medtronic, INC. | $17.56 | 2025 | Intellis Adaptivestim |
| Genentech USA, INC. | $16.73 | 2022 | |
| Sumitomo Pharma America, INC. | $16.32 | 2024 | Gemtesa |
| Amgen INC. | $15.74 | 2024 | Repatha, Otezla |
| Viiv Healthcare Company | $15.01 | 2025 | Apretude |
| Astellas Pharma US INC | $13.58 | 2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $12.27 | 2020 | |
| Dexcom, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.